Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 May;21(5):537–542. doi: 10.1111/j.1365-2125.1986.tb02839.x

Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgery.

J L Halperin, B P Mindich, E B Rothlauf, R F Reder, R S Litwak, J Kupersmith
PMCID: PMC1401022  PMID: 2872908

Abstract

Labetalol is a competitive inhibitor of alpha- and beta-adrenergic receptors and has an antihypertensive action. To determine limb haemodynamic effects, we measured calf blood flow and venous capacitance by venous occlusion plethysmography before and after oral labetalol in 10 patients 3-7 days following coronary bypass surgery. Vascular resistance was calculated as the ratio of mean arterial pressure to arterial flow. The peak effect of labetalol was taken as the point of maximum blood pressure decline, and this interval was selected for evaluation of the limb haemodynamic response. Ninety to 120 min after administration of 100-200 mg of labetalol the mean blood pressure fell from 88 +/- 3 to 79 +/- 3 mm Hg; (P less than 0.005). The mean arterial blood flow registered 5.1 +/- 1.0 ml 100 ml-1 limb tissue min-1 which was not significantly different from the control value of 4.4 +/- 0.8 ml 100 ml-1 limb tissue min-1. The calculated index of limb vascular resistance was not affected by labetalol administration, averaging 37 +/- 12 mm Hg 100-1 ml limb tissue min-1 before labetalol and 30 +/- 11 mm Hg ml-1 100 ml limb tissue min-1 at the time of peak hypotensive effect. There was a slight but statistically significant increment in limb venous volume to 1.9 +/- 0.3 from 1.5 +/- 0.3 ml 100 ml-1 limb tissue (P less than 0.025). Placebo administration produced no consistent changes in blood pressure, arterial blood flow, vascular resistance or venous capacitance.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
542

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baum T., Sybertz E. J. Pharmacology of labetalol in experimental animals. Am J Med. 1983 Oct 17;75(4A):15–23. doi: 10.1016/0002-9343(83)90132-8. [DOI] [PubMed] [Google Scholar]
  2. Brittain R. T., Levy G. P. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):681–684. [PubMed] [Google Scholar]
  3. Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Labetalol: a review of its pharmacology and therapeutic use in hypertension. Drugs. 1978 Apr;15(4):251–270. doi: 10.2165/00003495-197815040-00002. [DOI] [PubMed] [Google Scholar]
  4. Dage R. C., Hsieh C. P. Direct vasodilatation by labetalol in anaesthetized dogs. Br J Pharmacol. 1980 Oct;70(2):287–293. doi: 10.1111/j.1476-5381.1980.tb07934.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Estafanous F. G., Tarazi R. C. Systemic arterial hypertension associated with cardiac surgery. Am J Cardiol. 1980 Oct;46(4):685–694. doi: 10.1016/0002-9149(80)90521-4. [DOI] [PubMed] [Google Scholar]
  6. Farmer J. B., Kennedy I., Levy G. P., Marshall R. J. Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors. Br J Pharmacol. 1972 Aug;45(4):660–675. doi: 10.1111/j.1476-5381.1972.tb08125.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fouad F. M., Estafanous F. G., Tarazi R. C. Hemodynamics of postmyocardial revascularization hypertension. Am J Cardiol. 1978 Mar;41(3):564–569. doi: 10.1016/0002-9149(78)90016-4. [DOI] [PubMed] [Google Scholar]
  8. Frishman W., Halprin S. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol. Am Heart J. 1979 Nov;98(5):660–665. doi: 10.1016/0002-8703(79)90294-1. [DOI] [PubMed] [Google Scholar]
  9. Gagnon R. M., Morissette M., Présant S., Savard D., Lemire J. Hemodynamic and coronary effects of intravenous labetalol in coronary artery disease. Am J Cardiol. 1982 Apr 1;49(5):1267–1269. doi: 10.1016/0002-9149(82)90054-6. [DOI] [PubMed] [Google Scholar]
  10. Hartling O. J., Svendsen T. L., Trap-Jensen J. Haemodynamic and metabolic effects of combined adrenergic alpha- and beta-receptor blockade with labetalol in the exercising human forearm. Eur J Clin Invest. 1980 Dec;10(6):431–435. doi: 10.1111/j.1365-2362.1980.tb02081.x. [DOI] [PubMed] [Google Scholar]
  11. Hartling O. J., Svendsen T. L., Trap-Jensen J. Immediate haemodynamic and metabolic effects of intravenous labetalol in the exercising forearm. Postgrad Med J. 1980;56 (Suppl 2):17–20. [PubMed] [Google Scholar]
  12. Hoffman B. B., Lefkowitz R. J. Alpha-adrenergic receptor subtypes. N Engl J Med. 1980 Jun 19;302(25):1390–1396. doi: 10.1056/NEJM198006193022504. [DOI] [PubMed] [Google Scholar]
  13. Mehta J., Cohn J. N. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation. 1977 Feb;55(2):370–375. doi: 10.1161/01.cir.55.2.370. [DOI] [PubMed] [Google Scholar]
  14. Michelson E. L., Frishman W. H. Labetalol: an alpha- and beta-adrenoceptor blocking drug. Ann Intern Med. 1983 Oct;99(4):553–555. doi: 10.7326/0003-4819-99-4-553. [DOI] [PubMed] [Google Scholar]
  15. O'Grady J., Oh V., Turner P. Effects of propranolol and oxprenolol on the vasoconstrictor response to noradrenaline in the superficial hand vein in man. Eur J Clin Pharmacol. 1978 Nov 16;14(2):83–85. doi: 10.1007/BF00607435. [DOI] [PubMed] [Google Scholar]
  16. Smith R. S., Warren D. J. Effect of acute oral beta adrenergic blockade on muscle blood flow in man. Cardiovasc Res. 1982 Apr;16(4):205–208. doi: 10.1093/cvr/16.4.205. [DOI] [PubMed] [Google Scholar]
  17. Smith R. S., Warren D. J. Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication. J Cardiovasc Pharmacol. 1982 Jan-Feb;4(1):2–4. doi: 10.1097/00005344-198201000-00002. [DOI] [PubMed] [Google Scholar]
  18. Wallach R., Karp R. B., Reves J. G., Oparil S., Smith L. R., James T. N. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol. 1980 Oct;46(4):559–565. doi: 10.1016/0002-9149(80)90503-2. [DOI] [PubMed] [Google Scholar]
  19. Wallin J. D., O'Neill W. M., Jr Labetalol. Current research and therapeutic status. Arch Intern Med. 1983 Mar;143(3):485–490. doi: 10.1001/archinte.143.3.485. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES